摘要
原发性肝细胞肝癌(HCC)是常见的恶性肿瘤,中国每年约有50%的新发病例。改进肝癌风险人群高危预警和早筛、早诊策略,对提高肝癌患者5年生存率至关重要。建立科学且适合医疗机构和健康管理机构推广、应用的无创伤性血液检测技术是提升现有HCC诊断和随访有效性的关键途径之一。基于国内外相关指南、共识、文献和中国人群临床循证实践,中国康复医学会医学检验与康复专业委员会等机构共同制定《肝癌三项(AFP、AFP-L3%、DCP)与GALAD、类GALAD模型临床应用专家共识》,对肝癌三项[甲胎蛋白(AFP)、甲胎蛋白异质体百分比(AFP-L3%)、异常凝血酶原(DCP)]和基于肝癌三项的GALAD模型、类GALAD模型的临床意义、适用人群、检测技术、结果解读等提出建议,旨在提高肝癌三项无创检测临床应用的科学性、合理性和可操作性,最大程度地发挥其应用效能,助力提升中国肝癌人群高危预警和临床早诊能力,改善肝癌患者预后和生存质量。
Primary hepatocellular carcinoma(HCC)is a prevalent world-wide malignancy.Half of the newly developed HCC occurs in China.Optimizing the strategies for high-risk surveillance and early diagnosis is pivotal for improving 5-year survival.Constructing the scientific non-invasive determination technologies feasible for medical and healthcare institutions is a key route for elevating the efficacies in HCC diagnosis and follow-up.Based on the international and Chinese guidelines,expert consensus statements,literatures and evidence-based clinical practice experiences,this consensus published by the Clinical Laboratory Society of Chinese Association for Rehabilitation Medicine puts forward the clinical implications,application subjects,determination techniques and result interpretations for GALAD and GALAD-like models based on alpha-fetoprotein(AFP),alpha-fetoprotein heterogeneity-L3%(AFP-L3%),and des-gamma-carboxy prothrombin(DCP).The compile of this consensus statement aims to address and push the reasonable model application of the triple-biomarker(AFP,AFP-L3%,DCP)determinations thus to maximize the clinical efficacies and help improving HCC high-risk surveillance,early diagnosis and prognosis.
作者
中国康复医学会医学检验与康复专业委员会
上海市医学会分子诊断专科分会
上海市免疫学会肿瘤免疫分会
上海中医药大学附属岳阳中西医结合医院
上海市临床检验中心
中国中西医结合学会检验医学专业委员会
上海市抗癌协会检验医学专业委员会
上海市抗癌协会肿瘤标志物专业委员会
高春芳
黄晨军
肖潇
周琳
陈福祥
王见义
胡晓波
Clinical Laboratory Society of Chinese Association for Rehabilitation Medicine;Molecular Diagnostics Society of Shanghai Medical Association;Tumor Immunology Branch of Shanghai Society for Immunology;Yueyang Hospital of Integrated Traditional Chinese and Western Medicine of Shanghai University of Traditional Chinese Medicine;Shanghai Center for Clinical Laboratory;Clinical Laboratory Society of Chinese Association of Integrative Medicine;Clinical Laboratory Society of Shanghai Anticancer Association;Tumor Markers Society of Shanghai Anticancer Association.
出处
《检验医学》
CAS
2023年第7期607-623,共17页
Laboratory Medicine
基金
国家科技重大专项(2018ZX10302205-003)
上海市肿瘤分子医学协同创新项目(2019CXJQ03)。
关键词
甲胎蛋白
甲胎蛋白异质体百分比
异常凝血酶原
GALAD模型
肝细胞肝癌
Alpha-fetoprotein
Alpha-fetoprotein heterogeneity-L3%
Des-gamma-carboxy prothrombin
GALAD model
Hepatocellular carcinoma